Related by context. All words. (Click for frequent words.) 66 prior chemotherapy regimens 63 anthracycline taxane 63 metastatic NSCLC 58 imatinib therapy 56 stage IIIb IV 56 ribavirin therapy 55 HCV RESPOND 2 55 dosing cohorts 55 NYHA Class II 55 cytotoxic therapy 55 metastatic RCC 55 achieve sustained virologic 55 DMARD 55 unresectable 54 evaluable subjects 54 TNF inhibitor 54 pegylated interferon peg IFN 54 evaluable 54 dosing cohort 54 refractory NSCLC 54 HBeAg positive patients 54 Bcr Abl T#I mutation 54 metastatic GIST 54 heavily pretreated 54 Ph + ALL 53 metastatic SCCHN 53 #mg/m# [002] 53 irinotecan containing 53 metastatic HRPC 53 IV NSCLC 53 #mg QD [001] 53 cytogenetic response 53 virologic failure 53 achieved ACR# 53 stage IIIB 52 heavily pretreated patients 52 achieved PASI 52 infliximab therapy 52 anthracycline containing 52 sunitinib 52 ribavirin RBV 52 lymphoma CTCL 52 CCyR 52 colorectal cancer liver metastases 52 prospectively defined 52 IV tPA 52 mcg kg 52 dasatinib Sprycel ® 52 disease modifying antirheumatic 51 receptor tyrosine kinase inhibitor 51 resectable 51 EGFR TKI 51 placebo intravenously 51 partial remissions 51 IV metastatic melanoma 51 neoadjuvant chemotherapy 51 detectable HCV RNA 51 cytogenetic responses 51 undetectable HCV RNA 51 histologically confirmed 51 methotrexate therapy 51 lenalidomide Revlimid R 51 remission induction 51 docetaxel chemotherapy 51 AGILECT R 51 dacarbazine DTIC 51 T#I mutation 51 metastatic malignant melanoma 50 TNF antagonist 50 virological failure 50 recurrent glioblastoma multiforme 50 scissor lift serviced 50 IIIB NSCLC 50 drug DMARD 50 chronic plaque psoriasis 50 dose escalation phase 50 undergone splenectomy 50 oral rivaroxaban 50 alkylating agents 50 EGFR expressing mCRC 50 daily subcutaneous injections 50 gastrointestinal stromal tumor GIST 50 dose cohorts 50 ascending doses 50 DMARD therapy 50 metastatic pancreatic cancer 50 Bezielle 50 patients evaluable 50 mg/m2 50 TYSABRI therapy 50 blastic phase 50 nilotinib Tasigna ® 50 peg IFN 50 nucleoside naive 50 hepatitis C genotype 50 intravenous RSD# 50 chlorambucil 50 CRp 49 plus prednisone prednisolone 49 decompensated liver disease 49 refractory CLL 49 refractory CTCL 49 Median survival 49 HBeAg negative patients 49 DMARDs 49 infliximab 49 anthracycline therapy 49 HCV SPRINT 49 systemic ALCL 49 8mg/kg 49 anti rheumatic 49 relapsed CLL 49 placebo controlled clinical trials 49 myelodysplastic syndrome MDS 49 randomized #:#:# 49 oral vancomycin 49 leukemia AML 49 Tarceva TM 49 unresectable locally advanced 49 superficial bladder cancer 49 liver metastases 49 weekly subcutaneous injections 49 mitoxantrone chemotherapy 49 symptomatic BPH 49 APTIVUS r 49 naïve HCV 49 anti TNF alpha 49 #mg/m# [001] 49 Phase IIb trials 48 PEGINTRON TM 48 anthracyclines taxanes 48 fludarabine 48 undetectable HBV DNA 48 mg kg dose 48 neoadjuvant therapy 48 Phase 2a trial 48 venlafaxine ER 48 relapsed refractory multiple myeloma 48 relapsed 48 cell lymphoma CTCL 48 MCyR 48 advanced NSCLC 48 Navelbine ® 48 HCV genotype 1 48 pegylated interferon alpha 48 splenectomy 48 PREZISTA r 48 dose regimens 48 chemotherapy regimens 48 KRAS mutations occur 48 Doxil ® 48 Telintra 48 evaluable patients 48 REVIVE Diabetes 48 CML CP 48 FOLFOX4 48 eosinophilic asthma 48 RRMS patients 48 coronary revascularisation 48 refractory multiple myeloma 48 ABSORB trial 48 metastatic renal cell carcinoma 48 advanced metastatic renal 48 phase Ib 48 relapsed SCLC 48 dosed orally 48 tamoxifen therapy 48 talactoferrin 48 hepatic metastases 48 virological response 48 Pegasys ® 48 VEGF receptor inhibitor 48 FOLFIRI 48 IV melanoma 48 mRCC 48 inhaled tobramycin 48 remission CR 48 relapsed MM 47 receiving highly emetogenic 47 tumor shrinkage 47 achieved sustained virologic 47 biochemical relapse 47 COU AA 47 HBeAg negative 47 refractory acute myeloid 47 undergoing coronary angiography 47 eribulin 47 mg m² 47 standard chemotherapy regimens 47 virologically 47 chemotherapy regimen 47 irinotecan chemotherapy 47 dose dose escalation 47 AIR CF1 47 tumors GIST 47 FOLPI regimen 47 metastatic CRC 47 adjuvant therapy 47 metastatic renal cell 47 taxane chemotherapy administered 47 neurologic progression 47 ABRAXANE therapy 47 rapid virologic response 47 PegIFN RBV 47 neoadjuvant 47 relapsed GBM 47 anti TNF 47 unresectable stage 47 metastatic disease 47 recurrent NSCLC 47 relapsers 47 complete cytogenetic 47 ZALBIN dosed 47 underwent liver transplantation 47 treatment naïve genotype 47 adalimumab 47 renal cell carcinoma 47 active comparator 47 4mg/kg 47 defendant Vincenzo Cannalire 47 CYT# potent vascular disrupting 47 cetuximab Erbitux R 47 complete remissions 47 pegylated interferon alfa 2a 47 underwent CABG 47 NSCLC 47 weekly intravenous infusions 47 #mg QD [002] 47 hypercalcemia 47 resistant ovarian cancer 47 dirucotide MBP# 47 peginterferon 47 pegylated interferon 47 phase IIb study 47 null responders 47 antiretroviral naive 47 refractory Hodgkin lymphoma 47 lupus nephritis 47 autoantibody positive 47 adverse cytogenetics 47 OADs 47 motesanib 47 mcg albinterferon alfa 2b 47 recurrent malignant glioma 47 achieved sustained virological 47 blinded randomized placebo controlled 47 RESIST studies 47 relapsing remitting 47 recurrent genital herpes 47 Dryman disappeared 47 dacarbazine 47 oral antidiabetic agents 47 rALLy 47 stage IIIB IV 47 Stage IIIB IV 47 lymphoid blast 47 peginterferon alfa 46 baminercept 46 recurrent GBM 46 acute gout flares 46 HBeAg positive 46 forodesine 46 monotherapy 46 plus ribavirin 46 plus gemcitabine 46 riociguat 46 non splenectomized 46 amrubicin 46 HSCT 46 protease inhibitor PI 46 metastatic squamous cell carcinoma 46 EGFR expressing 46 interferon alfa 2b 46 administered subcutaneously 46 null responder HCV 46 metastatic castration resistant 46 EGFR mutation positive 46 dose escalation 46 unresectable Stage III 46 macroalbuminuria 46 dexanabinol 46 gefitinib 46 relapsing remitting MS RRMS 46 FLT3 mutations 46 Piedra Blanca emergency 46 refractory AML 46 leukemia APL 46 Thrombotic events 46 previously untreated follicular 46 depressive episode 46 BARACLUDE ® 46 delayed onset CINV 46 Exelixis compounds 46 imatinib 46 fallopian tube carcinoma 46 alkylating agent 46 subcutaneous enoxaparin 46 mg BID 46 mGluR5 NAM 46 acute GvHD 46 mg/m2/day 46 imatinib resistant 46 antidepressant therapy 46 lamivudine refractory patients 46 refractory metastatic 46 metastatic hormone refractory 46 treatment naive genotype 46 cutaneous T cell 46 ZOLINZA 46 tocilizumab 46 nonresponders 46 metastatic malignant 46 imatinib mesylate 46 sorafenib Nexavar 46 VFEND 46 induce remission 46 chronic GVHD 46 multiple myeloma MM 46 darunavir ritonavir 46 temsirolimus 46 efficacy endpoint 46 Dated announcements 46 B CLL 45 antiretroviral naïve 45 unique alkylating agent 45 interferon alfa 2a 45 VELCADE melphalan 45 chemoradiotherapy 45 NNRTI 45 peg interferon 45 taxane therapy 45 MAGE A3 ASCI 45 methotrexate MTX 45 allogeneic stem cell 45 CCR5 inhibitors entry 45 immune thrombocytopenic purpura ITP 45 ACTEMRA TM 45 intravenous belinostat 45 phase IIb clinical 45 galiximab 45 #mg ATC 45 myeloablative 45 vandetanib 45 taxane chemotherapy 45 adjunctive placebo 45 Still Wojtala 45 Myelodysplastic Syndrome MDS 45 metastatic CRPC 45 antiviral therapy 45 HRPC 45 sorafenib 45 nilotinib 45 adriamycin 45 estramustine 45 alfa 2a 45 cabazitaxel 45 bendamustine 45 HER2 positive metastatic breast 45 venlafaxine XR 45 SCCHN 45 dose dexamethasone 45 chemo radiotherapy 45 HAART regimen 45 receiving VICTRELIS 45 CR CRu 45 preoperative chemotherapy 45 fallopian tube cancers 45 aHUS 45 metastatic lung cancer 45 CANCIDAS 45 chemotherapy cisplatin 45 CIMZIA TM 45 nab paclitaxel 45 doxorubicin HCl liposome injection 45 Phase 2b study 45 refractory chronic myeloid 45 irinotecan 45 haematologic 45 metastatic kidney 45 hormone refractory prostate cancer 45 febrile neutropenia 45 lamivudine 45 carcinoma mCRC 45 TTF Therapy 45 wounded Ayubi 45 Phase IIa trial 45 dexamethasone Decadron 45 biologic therapy 44 progressive PsA 44 diagnosable mental illness 44 gefitinib Iressa 44 plus dexamethasone 44 gemifloxacin 44 dasatinib 44 hepatocellular carcinoma HCC 44 Solid Tumors criteria 44 mitoxantrone plus 44 sustained virologic response 44 docetaxel 44 plus prednisone 44 acute mania 44 cutaneous T 44 low dose cytarabine 44 FOLFOX6 44 visilizumab 44 standard chemotherapy regimen 44 mapatumumab 44 non myeloid malignancies 44 CHAMPION PCI 44 mg/m2 dose 44 5 fluorouracil 44 Response Evaluation Criteria 44 disease progression 44 outdid Eli Manning 44 systemic anaplastic large 44 pertuzumab 44 elacytarabine 44 untreated chronic lymphocytic 44 atherothrombotic events 44 LEXIVA r 44 Traficet EN 44 Mylotarg 44 Folfox 44 ZEGERID Chewable Tablets 44 bortezomib refractory 44 sustained virological response 44 erlotinib Tarceva ® 44 alvespimycin 44 idarubicin 44 interferon alfa 44 Registered Nurse w 44 interferon therapy 44 diagnosed Ph + 44 Sutent sunitinib 44 neoadjuvant treatment 44 PNP inhibitor 44 Amrubicin 44 brethren ye 44 refractory indolent NHL 44 prostate cancer HRPC 44 hypomethylating agents 44 thymoma 44 untreated de novo 44 immunomodulatory therapy 44 ragweed allergy immunotherapeutic 44 mitoxantrone 44 antiestrogen therapy 44 KIACTA ™ 44 chronic HCV genotype 44 Peg IFN 44 platinum refractory 44 relapsed refractory ALL 44 virologic response 44 rufinamide 44 HGS ETR1 44 TNF blocker therapy 44 rituximab 44 Epratuzumab 44 evaluating Xcytrin 44 interferon ribavirin 44 tyrosine kinase inhibitors 44 proprietary Knobias alert 44 mCRC patients 44 remitting MS 44 ponatinib 43 metastatic bladder 43 HCV infected 43 telaprevir dosed 43 leukemia CLL 43 alefacept 43 chronic myeloid leukemia CML 43 myelofibrosis 43 relapsed MCL 43 YONDELIS 43 relapsed myeloma 43 Paxil paroxetine 43 relapsed refractory 43 carboplatin 43 CRu 43 free survival PFS 43 Tasigna prolongs 43 anti leukemic 43 Alemtuzumab 43 arbaclofen 43 CHOP chemotherapy 43 sorafenib Nexavar ® 43 risperidone Risperdal 43 severe oral mucositis 43 FOLFOX 43 IMPACT DCM trial 43 splenectomized patients 43 refractory indolent non 43 Morningstar calculates 43 placebo dexamethasone 43 IIIA NSCLC 43 TNF inhibitors 43 peginterferon alfa 2a 43 EOquin TM 43 seroconverted 43 untreated CLL 43 differentiated thyroid 43 Massetti testified 43 dirucotide 43 glufosfamide 43 refractory gout 43 class mGluR5 inhibitor 43 tofacitinib 43 gemcitabine carboplatin 43 cancer mCRC 43 leukemia ALL 43 progression TTP 43 refractory cutaneous T 43 RECIST criteria 43 relapsed Acute Myeloid 43 pegylated interferon alpha 2a 43 myelodysplastic syndromes MDS 43 colorectal liver metastases 43 chemoradiation 43 Hodgkin lymphoma HL 43 primary hypercholesterolemia 43 diagnosed GBM 43 refractory chronic lymphocytic 43 non metastatic osteosarcoma 43 untreated AML 43 aged ≥ 43 pomalidomide 43 abatacept 43 CLL SLL 43 ASCT 43 lamotrigine 43 completed Abrames 43 TORISEL 43 steroid refractory ulcerative 43 Pharmacokinetics PK 43 lamivudine monotherapy 43 stopping Nyhart 43 HIV uninfected 43 cisplatin chemotherapy 43 cytotoxic chemotherapy 43 peginterferon alfa 2b 43 relapsing remitting MS 43 desvenlafaxine succinate 43 hematologic 42 gastrointestinal stromal tumors GIST 42 gemcitabine chemotherapy 42 linezolid 42 eculizumab 42 Diganta television 42 biliary tract cancer 42 lumiliximab 42 Phase 1b trial 42 sports@thevillagesmedia.com 42 refractory systemic ALCL 42 unresectable recurrent 42 Raloxifene Evaluation MORE 42 stent thromboses 42 refractory myeloma 42 continuously abstinent 42 etanercept 42 rindopepimut 42 docetaxel Taxotere R 42 clodronate 42 RoACTEMRA 42 prescribe Paxil 42 azacitidine 42 chronic lymphocytic leukemia CLL 42 OHR/AVR# 42 doublet chemotherapy 42 nortriptyline 42 advanced carcinoid 42 imatinib mesylate Gleevec 42 MGd 42 relapsed leukemia 42 Hodgkin lymphoma NHL 42 transcriptase inhibitor NNRTI 42 retreatment 42 olmesartan 42 Phase III HEAT 42 Free Survival PFS 42 adjuvant chemotherapy 42 relapsing remitting multiple sclerosis 42 AYP benchmarks 42 diuretics antibiotics 42 HbA1c levels 42 Dr. Ahmed Nasrat 42 cyclophosphamide methotrexate 42 carboplatin paclitaxel 42 spokeswoman Claudine Shacklock 42 relapsed AML 42 fluorouracil 42 oral methylnaltrexone 42 randomized controlled multicenter 42 dosing regimens 42 doxorubicin cyclophosphamide 42 mycophenolate mofetil 42 romiplostim 42 idiopathic thrombocytopenic purpura ITP 42 Cutaneous T 42 gemcitabine 42 approve Arcoxia 42 rituximab refractory 42 velaglucerase alfa 42 zoledronic acid 42 taxane refractory 42 EGFR tyrosine kinase inhibitor 42 unblinded 42 leukemia CML 42 mastectomy chemotherapy 42 KRAS mutant tumors 42 pegylated interferon alfa 42 adalimumab Humira 42 cancer neuroendocrine tumor 42 relapsing MS 42 plasma uric acid 42 TACE 42 administered orally 42 cetuximab Erbitux ® 42 bevacizumab Avastin ® 42 got Abbott MitraClip 42 valproate 42 HER2 negative 42 Brock Kelson died 42 castration resistant prostate cancer 42 Researchers randomly assigned 42 PegIntron 42 de novo kidney transplant 42 Swedish Mammography Cohort 42 TIME Delivery 42 clinically meaningful differences 42 goserelin 42 TMC# C# 42 HGS# 42 refractory ovarian cancer 42 Pemetrexed 42 axitinib 42 myelogenous leukemia 42 underwent percutaneous coronary 42 randomized #:# 42 chemoradiation therapy 42 chronic myeloid 41 imatinib Gleevec 41 pediatric malignancies 41 Fludara 41 Flu Cy 41 5-FU/LV 41 divalproex 41 progressive MS SPMS 41 methotrexate 41 blinded placebo controlled 41 SPRYCEL ® 41 treatment regimens 41 cilengitide 41 olaparib 41 OPT CHF 41 iniparib 41 docetaxel Taxotere 41 FluCAM 41 acute leukemias 41 refractory colorectal cancer 41 auer@siadvance.com 41 Toxicities 41 demonstrated antitumor activity 41 glioblastoma 41 chickenpox vaccinations 41 DFMO 41 Anticipating Flossie 41 metastatic breast cancer 41 partial onset seizures 41 Rosuvastatin JUPITER 41 recurrent ovarian cancer 41 anthracycline 41 dose escalation clinical 41 dasatinib Sprycel 41 Phase 2a clinical 41 imatinib Gleevec ® 41 Fatalistic kids 41 trastuzumab Herceptin ® 41 CR nPR 41 cyclophosphamide 41 CINQUIL 41 lopinavir r 41 trabectedin 41 www.amazon.com ir 41 watcher Mark Zandi 41 opioid induced constipation OIC 41 Annamycin 41 vinorelbine 41 Campus Trendz Boutique 41 By NBC# NBC# 41 Cytoxan 41 median PFS 41 http:/www.bio-rad.com 41 No Snoopy bedsheets 41 budesonide MMX Phase III 41 ritonavir boosted 41 progressive psoriatic arthritis 41 Jevtana 41 http:/www.microsoft.com/windows/windowsmedia/downNyendo 41 frank.denzler @ cnhiindiana.com 41 myelofibrosis MF 41 glioblastoma multiforme GBM 41 Newly Diagnosed Multiple Myeloma 41 REVLIMID lenalidomide 41 panitumumab Vectibix 41 Waldenstrom macroglobulinemia 41 pemetrexed 41 anaplastic astrocytoma 41 bosentan 41 molindone 41 RGT arm 41 chemotherapies 41 mg/m2 cohort 41 dietary questionnaires 41 espnritt@gmail.com 41 divalproex sodium 41 cytarabine daunorubicin 41 controlled multicenter 41 Tornadoes devastate South 41 acute myelogenous leukemia AML 41 bortezomib 41 huN# DM1 41 pegylated liposomal doxorubicin 41 Adjuvant chemotherapy 41 relapsed acute myelogenous 41 subcutaneous methylnaltrexone 41 drugs DMARDs 41 randomized 41 indolent NHL 41 dexamethasone 41 ORAL HYCAMTIN 41 metastatic dermatofibrosarcoma protuberans DFSP 41 Liveauctioneers.com bidders represent 41 docetaxel prednisone 41 hormonal therapy 41 refractory CML 41 recurrent metastatic melanoma 41 oral COTI 40 telaprevir dosing 40 chronic HCV 40 tiotropium 40 pancreatic NET 40 late Maciel fathered 40 www.AnthonySamad.com 40 depressive episodes 40 prodromal symptoms 40 temozolomide 40 BRIM3 40 www.wabashnational.com within 40 virus HCV protease inhibitor 40 metastatic melanoma 40 solid tumors 40 indolent follicular non 40 raltegravir 40 cytarabine 40 Tamibarotene 40 fasting triglyceride levels 40 idiopathic thrombocytopenic purpura 40 refractory metastatic colorectal cancer 40 Gleevec imatinib 40 hormone receptor positive 40 ruben.vives @ latimes.com 40 Physician referral 40 indieWIRE Updated 40 stage IIIb 40 refractory HL 40 cell carcinoma RCC 40 Lauren Petitbois 40 PSADT 40 solanezumab 40 macroglobulinemia 40 MabCampath 40 refractory MCL 40 referencing passcode # # 40 octreotide 40 refractory ALCL 40 untreated multiple myeloma 40 Phase Ib 40 FOLFOX chemotherapy 40 prostate cancer CRPC 40 Arzerra ofatumumab 40 Tarceva erlotinib 40 NSABP C 40 Chronic Myeloid Leukemia 40 KRAS wild 40 www.oshkoshcorporation.com 40 treatment naļve 40 recurrent glioblastoma 40 gastrointestinal stromal tumors 40 cell chronic lymphocytic 40 oral naltrexone 40 hyper texters 40 Hardcover releases 40 Myelofibrosis 40 psychiatric hospitalization 40 Omacetaxine 40 Philadelphia Chromosome Positive 40 SPRYCEL 40 regorafenib 40 metastatic colorectal cancer 40 Acute Myeloid Leukaemia AML 40 label dose escalation 40 uric acid lowering 40 antiretroviral regimen 40 Telcyta 40 IMGN# 40 abiraterone 40 relapsed multiple myeloma 40 dysthymia 40 Secondhand smoke contains 40 velafermin 40 Barbara Perrucci Neighborhood 40 stands Choucair 40 cediranib 40 valopicitabine 40 mCRC 40 mycophenolate mofetil MMF 40 refractory peripheral T 40 erlotinib 40 refractory acute promyelocytic 40 phase 2a 40 quetiapine 40 PRECISE Trial 40 metastatic prostate cancer 40 phase Ph + 40 P 3C Orions maritime 40 Dual eligibles 40 everolimus tablets 40 platelet transfusions 40 vanEnglesdorp 40 targeting refractory relapsing 40 FOLFIRI alone 40 Primary Surface Condition 40 heaviest barrages 40 alive Ljiljana Karadzic 40 cancer recurred 40 Chumikova 40 follicular NHL 40 lipid lowering medications 40 IIa clinical trial 40 dose escalation trial 40 boat sinkings 40 lenalidomide 40 chintzy Halloween costume 40 Anbar Diyala Salahuddin 40 Dacogen injection 40 hypothermia bruises 39 lymphoid malignancies 39 Stage IIIb IV 39 capecitabine 39 initiate Phase 1b 39 Maj. Falah al Mihamadawi 39 hospitalized Streck 39 Phase 2a 39 ulcerative colitis UC 39 pazopanib 39 relapsing multiple sclerosis 39 myelodysplastic syndromes 39 del Caribe canceled 39 Myelodysplastic Syndrome 39 funnest Modano 39 Gemzar ® 39 Cloretazine 39 HER2 positive breast cancer 39 rwolf@redbluffdailynews.com 39 ENGAGE AF TIMI 39 Acute Myelogenous Leukemia AML 39 abatacept Orencia 39 Velcade bortezomib 39 cjeromecrow@hotmail.com 39 refractory lymphoma 39 Depressed bipolar 39 Cloretazine ® 39 Acute Myeloid Leukaemia 39 cell acute lymphoblastic 39 oxaliplatin 39 bevacizumab Avastin 39 operable breast cancer 39 azathioprine 39 Refractory Hodgkin Lymphoma 39 IIa trial 39 prescribed statins 39 brain metastases 39 Balu Balakrishnan owns 39 COPAXONE ® 39 annese@siadvance.com 39 terrydillman@newportnewstimes.com 39 clocked #:#.# [001] 39 Roddick Petitbois 39 Kaplan Meier curve 39 ARMS averaged 39 mgmt exper 39 refractory 39 gemcitabine Gemzar ® 39 systemic ALCL patients 39 antimilitary protest 39 randomly assign 39 Medellin brother Vernancio 39 paclitaxel Taxol R 39 Gleevec imatinib mesylate 39 sports@dailyillini.com 39 fdonnelly@siadvance.com 39 N#HSWD 39 www.clinicaltrials.gov 39 Fast Track designations 39 Sprycel dasatinib 39 Gebril Hewadi doctor 39 Xcytrin 39 receiving TEMODAR 39 Chronic Myelogenous Leukemia CML 39 sunitinib Sutent ® 39 Study ARIC 39 economically disadvantaged subgroup 39 relapse 39 Kenneth Tarpey owns 39 refractory APL 39 risperidone olanzapine 39 cirrhotic 39 By GlobalGrind Staff 39 spittin nails right 39 Taxotere ® 39 Gleevec resistant 39 diagnosed glioblastoma multiforme 39 undergo colonoscopy 39 retrospective cohort 39 Zabit Khan local 39 anne hi i 39 QD dosing 39 www.hgsi.com 39 Japan Kama Chinen 39 NO EXCEPTIONS Payment 39 ofatumumab 39 trastuzumab Herceptin R 39 Relapsed 39 NOXAFIL Oral Suspension 39 Onrigin 39 definitively diagnose 39 ixabepilone 39 Rapist jailed 39 CVP chemotherapy 39 sports@tigerweekly.com 39 CAELYX 39 ABSORB clinical 39 trastuzumab 39 abiraterone acetate 39 potentially hepatotoxic 39 Myriad Flurizan 39 tetanus diphtheria acellular pertussis 39 ER CHOP 39 sosa@hutchinsonleader.com 39 EQUIP OB 39 Pleasant Grove subdivision 39 Diffuse Large B 39 nutritionists cringe 38 controlled dose escalation 38 redeemed Absher 38 citalopram 38 Steffen fingertip got 38 hospitalized Worapot 38 Median PFS 38 refractory DLBCL 38 Measurable precipitation 38 infusional 5-FU/LV 38 PASI score 38 Chevalier Mayes may 38 relapsed indolent NHL 38 refractory PTCL 38 Bortezomib 38 rituximab refractory follicular 38 CONQUER OB 38 mabernethy@freedomenc.com 38 mercaptopurine 38 cell lymphoma PTCL 38 ovarian carcinoma 38 lintuzumab 38 leukapheresis procedure 38 FavId 38 EMPOWER Study 38 enrolled 38 oblimersen 38 denosumab oncology clinical trials 38 mutated KRAS gene 38 inappropriately lovestruck 38 non metastatic resectable 38 Glioblastoma Multiforme 38 Narmgui 38 Fludarabine 38 Herceptin trastuzumab 38 Reporter Chauna Aguilar 38 Seagal Normand 38 sunitinib malate 38 Phase 1b 38 Ribavirin 38 dose regimen 38 refractory SCLC 38 ARMs averaged #.# 38 academically proficient 38 6 mercaptopurine 38 registrational 38 pegfilgrastim